Solesence Inc

Solesence Inc (SLSN) Stock Analysis

$0.950

-0.005 (-0.51%)At close

Loading chart…
High
0.985
Open
0.955
VWAP
0.96
Vol
5.05K
Mkt Cap
Low
0.950
Amount
4.86K
EV/EBITDA, TTM
0.00

Solesence, Inc., formerly Nanophase Technologies Corporation, provides healthcare solutions across beauty and life science categories. It is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The Company partners with global and indie brands, leveraging its proprietary Active Stress Defense technology suite (Original Active Stress Defense, Kleair, and Bloom) to bring environmental protection beauty products to market via over a dozen market-ready offerings that embrace self-expression, health care, and self-care across skin care and color cosmetic categories. It also offers custom development, with turnkey options available across all paths to market. The Company’s products are formulated using its own mineral sunscreen actives, which are produced in its Chicagoland facility where it has been producing sunscreen actives, including the zinc oxide sunscreen active.

AI analysis of Solesence Inc (SLSN)

hold

Solesence, Inc. is currently trading at $0.95, with a forward P/E of 11.36, indicating potential undervaluation. However, the company has a significant year-to-date change of -36.67% and a one-year change of -73.83%, reflecting ongoing profitability challenges. The recent earnings report showed a net loss of $0.76 million in Q1 2026, which raises concerns about its financial stability. The RSI is at 47.23, suggesting it is neither overbought nor oversold, indicating a neutral technical position. Given these factors, it may be wise to hold rather than buy at this time, as the risks outweigh the potential rewards.

Valuation Metrics

The current forward P/E ratio for Solesence Inc (SLSN) is 11.36, compared to its 5-year average forward P/E of 5.89.

Forward P/E

Fair
5Y Average P/E
5.89
Current P/E
11.36
Overvalued
12.48
Undervalued
-0.69

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for SLSN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SLSN

$4.63

Scenario price

B

Base

Base · 50%SLSN

$4.55

Scenario price

B

Bear

Bear · 25%SLSN

$3.96

Scenario price

Events Timeline

2026-08-19 (ET)

17:30:00

Solesence Focuses on Operational Execution and Financial Discipline

2026-02-26 (ET)

08:20:00

Solesence Appoints Yoolie Park as VP of Brand Partnerships

2025-11-11 (ET)

07:01:26

Solesence announces Q3 earnings per share of 2 cents, down from 4 cents a year ago.

2025-11-10 (ET)

08:26:47

Solesence names Yoana Dvorzsak as Vice President of Innovation and Product Integrity

2025-09-03 (ET)

08:09:27

Solesence names Kevin Cureton as its new president and CEO.

News

SLSN FAQ — answered by Alphio AI

Solesence, Inc., formerly Nanophase Technologies Corporation, provides healthcare solutions across beauty and life science categories. It is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The Company partners with global and indie brands, leveraging its proprietary Active Stress Defense technology suite (Original Active Stress Defense, Kleair, and Bloom) to bring environmental protection beauty products to market via over a dozen market-ready offerings that embrace self-expression, health care, and self-care across skin care and color cosmetic categories. It also offers custom development, with turnkey options available across all paths to market. The Company’s products are formulated using its own mineral sunscreen actives, which are produced in its Chicagoland facility where it has been producing sunscreen actives, including the zinc oxide sunscreen active. It operates in the Consumer Non-Cyclicals sector.

Solesence, Inc. is currently trading at $0.95, with a forward P/E of 11.36, indicating potential undervaluation. However, the company has a significant year-to-date change of -36.67% and a one-year change of -73.83%, reflecting ongoing profitability challenges. The recent earnings report showed a net loss of $0.76 million in Q1 2026, which raises concerns about its financial stability. The RSI is at 47.23, suggesting it is neither overbought nor oversold, indicating a neutral technical position. Given these factors, it may be wise to hold rather than buy at this time, as the risks outweigh the potential rewards.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started